biostudies-literatureUnknown20(1)Cannata-Andia JB<h4>Background</h4>Vitamin D status has been implicated in COVID-19 disease. The objective of the COVID-VIT-D trial was to investigate if an oral bolus of cholecalciferol (100,000 IU) administered at hospital admission influences the outcomes of moderate-severe COVID-19 disease. In the same cohort, the association between baseline serum calcidiol levels with the same outcomes was also analysed.<h4>Methods</h4>The COVID-VIT-D is a multicentre, international, randomised, open label, clinical trial conducted throughout 1 year. Patients older than 18 years with moderate-severe COVID-19 disease requiring hospitalisation were included. At admission, patients were randomised 1:1 to receive a single oral bolus of cholecalciferol (n=274) or nothing (n=269). Patients were followed from admission to BMC medicine83https://www.ebi.ac.uk/biostudies/studies/S-EPMC8853840biostudies-literatureA single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial.PMC8853840Fernandez-Martin JLHerrero-Puente PPalomo-Antequera CCunningham JPanizo SNaves-Diaz MMouzo RIbanez GHPefaur-Penna JDouthat WCannata-Andia JBSanchez-Polo VGomez-Alonso CGomez MDCusumano CACarrillo-Lopez NBallarino CMaderuelo-Riesco ICalvino-Varela JFernandez PCOVID-VIT-D trial collaboratorsDiaz-Sottolano AfalseA single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial.<h4>Background</h4>Vitamin D status has been implicated in COVID-19 disease. The objective of the COVID-VIT-D trial was to investigate if an oral bolus of cholecalciferol (100,000 IU) administered at hospital admission influences the outcomes of moderate-severe COVID-19 disease. In the same cohort, the association between baseline serum calcidiol levels with the same outcomes was also analysed.<h4>Methods</h4>The COVID-VIT-D is a multicentre, international, randomised, open label, clinical trial conducted throughout 1 year. Patients older than 18 years with moderate-severe COVID-19 disease requiring hospitalisation were included. At admission, patients were randomised 1:1 to receive a single oral bolus of cholecalciferol (n=274) or nothing (n=269). Patients were followed from admission to 2022-01-01T00:00:00Z2022 Feb2026-05-31T01:19:27.324Z2022-07-11T15:07:24.32ZS-EPMC88538403517706610.1186/s12916-022-02290-8